NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer.JAMA, 264: 1444–1450, 1990.
4.
PrehnR.T.: The inhibition of tumor growth by tumor mass.Cancer Res., 51: 2–4, 1991.
5.
GoldieJ.H., ColdmanA.J.: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.Cancer Treat. Rep., 63: 1727–1733, 1979.
6.
GoldieJ.H., ColdmanA.J.: Quantitative model for multiple levels of drug resistance in clinical tumors.Cancer Treat. Rep., 67: 923–931, 1983.
7.
HeidelbergerC., ChandariN.K., DannembergP.: Fluorinated pyrimidines: a new class of tumor inhibitory compounds.Nature, 179: 663, 1957.
8.
SaltzL.: Drug treatment of colorectal cancer.Drugs, 42: 616–627, 1991.
9.
SaptiD.V., McHenryC.S., RainesR.T., IvanetichK.M.: Kinetics and thermodinamics of the interaction of 5-fluoro-2-deossyuridylate and thymidylate synthase.Biochemistry, 26: 8606, 1987.
10.
RustumY.M.: Modulation of fluoropyrimidines by leucovorin: rationale and status. J. Surg.Oncol., 2(suppl): 116–123, 1991.
11.
MiniE., TraveF., RustumY.M.: Enhancement of the antitumor effects of 5-fluorouracil by folinic acid.Pharmacol. Ther., 47: 1–19, 1990.
12.
Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate.J. Clin. Oncol., 10: 896–903, 1992.
13.
CadmanE.D., HeimarR., DavisL.: Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism.Science, 205: 1135–1137, 1979.
14.
BenzC., CadmanE.: Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal carcinoma HCT-8.Cancer Res., 41: 994–999, 1981.
15.
RadererM., ScheithauerW.: Treatment of advanced colorectal cancer with 5-FU and interferon alpha: an overview of clinical trials.Eur. J. Cancer, 31: 1002–1008, 1995.
16.
SobreroA.F., AscheleC., GuglielminiA.: Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer.Clin. Cancer Res., 1: 955–960, 1995.
17.
MaybaumJ., UllmanB., MandelH.G.: Regulation of RNA and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells.Cancer Res., 40: 4209–4215, 1980.
18.
AscheleC., SobreroA.F., FaderanM.A.: Novel mechanism of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.Cancer Res., 52: 1855–1864, 1992.
19.
MoriA., BertoglioS., GuglielminiA.: Activity of continuous infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil.Cancer Chemother. Pharmacol., 33: 179–180, 1993.
20.
SobreroA.F., AscheleC., GuglielminiA.: Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells.J. Natl. Cancer Inst., 85: 1937–1944, 1993.
21.
de GramontA., BossetJ.F., MilanC.: Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study.J. Clin. Oncol., 15: 808–815, 1997.
22.
Diaz RubioE., ZaniboniA., GastaburuJ.: Phase II multicentric trial of oxaliplatin (L-OHP) as first line chemotherapy in metastatic colorectal carcinoma.Proc. Am. Soc. Clin. Oncol., 207: 15, 1996.
23.
MachoverD., Diaz RubioE., de GramontA.: Two consecutive studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.Ann. Oncol., 7: 95–98, 1996.
24.
LevìF., ZidaniR., MissetJ.L.: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer.Lancet, 350: 681–686, 1997.
25.
RousselotL.M., ColeD.R., GrossiC.E.: Intraluminal chemotherapy (HN2 of 5-FU).Adjuvant to operation for cancer of the colon and rectum. Cancer, 20: 829–833, 1967.
26.
GrossiC.E., WolfW.I., NealonT.F.: Intraluminal fluorouracil chemotherapy adjuvant to surgical procedure of resectable carcinoma of the colon and rectum.Surg. Gyn. Obst., 145: 549, 1977.
27.
LawrenceW., TerzJ.J., HorsleyS.: Chemotherapy as adjuvant to surgery for colorectal cancer.Ann. Surg., 181: 616–623, 1975.
28.
GrageT.B., MossS.E.: Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled randomised trial.Surg. Clin. North Am., 61: 1321, 1981.
29.
HigginsG.A., LeeL.E., DwightR.W.: The case for adjuvant 5-fluorouracil in colorectal cancer.Cancer Clin. Trials, 1: 35, 1978.
30.
HigginsG.A., AmadeoJ.H., McElhinneyJ.: Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel.Cancer, 53: 1–8, 1984.
31.
PannettiereF.J., GoodmanP.J., CostanziJ.J.: Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study.J. Clin. Oncol., 6: 948–994, 1988.
32.
MansourE.G., McIntyreJ.W., JohnsonR.: Adjuvant studies in colorectal carcinoma: experience of the Eastern Cooperative Group (ECOG). Preliminary report. In: GerardA. (Ed.), Progress and perspectives in the treatments of gastrointestinal tumours, pp. 68–75, Pergamon Press, New York1981.
33.
WolmarkN., FisherB., RocketteH.: Post-operative chemotherapy or BCG for colorectal cancer: results from NSABP protocol C-01.J. Natl. Cancer Inst., 80: 30–36, 1988.
34.
BuyseM., Zeleniuch-JacquotteA., ChalmersT.C.: Adjuvant therapy of colorectal cancer.Why we still don't know. JAMA, 259: 3571–3578, 1988.
35.
MoertelC.G., FlemingT.R., MacDonaldJ.S.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.N. Engl. J. Med., 332: 352–58, 1990.
36.
MoertelC.G., FlemingT., MacDonaldJ.S.: Fluorouracil and levamisole as effective adjuvant therapy after resection of stage III colon carcinoma.A final report. Ann. Intern. Med., 122: 321–326, 1995.
37.
IMPACT trial: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer.Lancet, 345: 939–944, 1995.
38.
O'ConnellM., MaillardJ., MacDonaldJ.S.: Controlled trial of fluorouracil and low dose leucovorin given for six months as post-operative adjuvant therapy for colon cancer.J. Clin. Oncol., 15: 246–250, 1997.
39.
WolmarkN., RocketteH., FisherB.: The benefit of leucovorin modulated 5-fluorouracil as postoperative adjuvant treatment for primary colon cancer: results from the Natl Surg Adjuv Breast and Bowel Project protocol C-03.J. Clin. Oncol., 11: 1879–1888, 1993.
40.
ZaniboniA.: Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival?J. Clin. Oncol., 15: 2432–2441, 1997.
41.
HallerD.G., CatalanoP.J., MacDonaldJ.S.: Eastern Cooperative Oncology Group (SWOG), Southwest Oncology Group (SWOG), Cancer and Acute Leukemia Group B (CALGB).Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer. Preliminary results of INT-0089. Proc. Am. Soc. Clin. Oncol., 15: 211, 1996.
42.
O'ConnelM.J., LaurieJ.A., StepherdL.: A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group and the National Cancer Institute of Canada Trials Group.Proc. Am. Soc. Clin. Oncol., 15: 209, 1996.
43.
WolmarkN., RocketteH., MamounasE.P.: The relative efficacy of 5-FU + leucovorin, 5-FU + levamisole, and 5-FU + leucovorin + levamisole in patients with Dukes’ B and C carcinoma of the colon: first report of NSABP C-04.Proc. Am. Soc. Clin. Oncol., 15: 205, 1996.
44.
RougierP.: Current controversies in cancer: is there a standard adjuvant treatment for colon rectal cancer?Contra. Eur. J. Cancer, 34: 1655–1659, 1998.
45.
RiethmullerG., Schneider-GadickeE., SchlimokG.: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma.Lancet, 343: 1177–1183, 1994.
46.
LiefersG.J., Cleton-JansenA.M., van de VeldeC.J.H.: Micrometastases and survival in stage II colorectal cancer.N. Engl. J. Med., 339: 223–228, 1998.
47.
MoertelC.G., FlemingT., MacDonaldJ.S.: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer.J. Clin. Oncol., 13: 2936–2943, 1995.
48.
LabiancaR.: Proc ASCO1999, in stampa.
49.
ZaniboniA., LabiancaR., MarsoniS.: GIVIO=SITAC-01: a randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma: long-term result and evaluation of the indicators of health-related quality of life.Cancer, 82: 2135–2144, 1998.
